3d agoThe FlyBEARISH 42Analyst
Archived explainer. For the current picture see today's BCRX page.
Why Is BIOCRYST PHARMACEUTI (BCRX) Stock Down Today?
By the Top Tier Newswire AI Desk · September 10, 2026 at 9:45 AM ET · reviewed against 3 wire stories
BIOCRYST PHARMACEUTI (BCRX) is down -7.55% in the latest session. Our newswire has captured 3 stories on BCRX across 3 sources in the last 36 hours, with AI sentiment reading mixed (avg 54/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
Why BCRX stock is down today
BioCryst Pharmaceuticals shares fell 7.55% in pre-market trading on Thursday to $8.14. The decline followed a downgrade from RBC Capital, which cut the stock to Sector Perform from Outperform. The move comes amid broader market weakness and mixed analyst coverage, with some maintaining bullish positions while others have reduced their outlook.
What Happened
RBC Capital’s downgrade was the most immediate catalyst for the stock’s decline. The firm adjusted its rating to Sector Perform from Outperform, signaling a shift in its relative confidence in BioCryst’s performance compared to its peers. This downgrade occurred alongside a broader sell-off in the market, with several large stocks falling in pre-market trading. Meanwhile, BioCryst announced a partnership with CareMed to expand the distribution of Orladeyo, its treatment for hereditary angioedema. However, the news failed to offset the negative sentiment from the downgrade.
The company remains unprofitable with a trailing twelve-month net margin of -40.9% and an earnings per share of -1.68. Despite a 68.7% year-to-date revenue increase, the stock has struggled to maintain momentum. Recent coverage has highlighted BioCryst as part of a group of healthcare stocks with strong revenue growth but mixed valuation grades.
What The Data Shows
The stock opened at $8.66, reflecting a -1.6% gap from the prior close. It quickly declined to an intraday low of $8.05 before stabilizing slightly. The session volume of 1.0 million shares is 0.2 times the 3-month daily average, indicating limited liquidity. The stock has now printed two fresh 52-week lows on September 10. Sentiment has deteriorated in the last seven days, with an average score of 53 out of 100, down from 60 over the past 30 days.
What To Watch
BioCryst has no scheduled earnings report in the near term. Investors should monitor the breadth of analyst coverage and any further updates on the company’s partnership with CareMed.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
BCRX by the numbers
Last: $8.14Session: -7.55%Coverage: 3 stories / 3 sourcesAI sentiment: 54/100 (mixed)Mkt cap: $2.3B52w: $6.00 to $11.22
The headlines behind the move
3d agoSeeking AlphaBULLISH 57Analyst
Ten healthcare stocks with A-rated valuations and strong revenue growth
Screened healthcare stocks with A/A+ valuation grades, ranked by YoY revenue growth—BCRX, NBIX, HRMY and more.
4d agoGlobeNewswireBULLISH 63Product/PR
CareMed Has Been Selected as a National Pharmacy Partner by BioCryst and Adds Orladeyo® (berotralstat) to Growing Rare Disease Portfolio
NEW HYDE PARK, N.Y., Sept. 08, 2026 (GLOBE NEWSWIRE) -- CareMed, an independent specialty pharmacy, has been selected as a pharmacy partner by BioCryst Pharmaceuticals for Orladeyo ® (berotralstat), a plasma kallikrein inhibitor...
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →
More on BCRX: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.
Earlier BCRX move explainers: 2026-09-10 · 2026-09-09 · 2026-09-08 · 2026-08-28